Thromb Haemost 2005; 93(02): 228-235
DOI: 10.1160/TH04-09-0578
Review Article
Schattauer GmbH

Circulating endothelial cells

Biomarker of vascular disease
Andrew D. Blann
1   Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
,
Alexander Woywodt
2   Department of Medicine, Division of Nephrology, Hannover Medical School, Hanover, Germany
,
Francesco Bertolini
3   Division of Haematology-Oncology, European Institute of Oncology, Milan, Italy
,
Todd M. Bull
4   Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
,
Jill P. Buyon
5   Division of Rheumatology, Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA
,
Robert M. Clancy
5   Division of Rheumatology, Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA
,
Marion Haubitz
2   Department of Medicine, Division of Nephrology, Hannover Medical School, Hanover, Germany
,
Robert P. Hebbel
6   Vascular Biology Centre and Division of Hematology-Oncology-Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
,
Gregory Y. H. Lip
1   Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
,
Patrizia Mancuso
3   Division of Haematology-Oncology, European Institute of Oncology, Milan, Italy
,
Jose Sampol
7   INSERM 608, Laboratoire d’Hematology et Immunology, UFR Pharmacie, Université de la Méditerranée, Marseille, France
,
Anna Solovey
6   Vascular Biology Centre and Division of Hematology-Oncology-Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
,
Françoise Dignat-George
7   INSERM 608, Laboratoire d’Hematology et Immunology, UFR Pharmacie, Université de la Méditerranée, Marseille, France
› Author Affiliations
Further Information

Publication History

Received 09 September 2004

Accepted after revision 28 January 2004

Publication Date:
11 December 2017 (online)

Zoom Image

Summary

Recent research has recognised new populations of non-hematopoïetic cells in the blood. One of these, circulating endothelial cells (CECs), often defined by the expression of membrane glycoprotein CD146, are rarely found in the blood in health, but raised numbers are present in a wide variety of human conditions, including inflammatory, immune, infectious, neoplastic and cardiovascular disease, and seem likely to be evidence of profound vascular insult. An additional population are endothelial progenitor cells, defined by the co-expression of endothelial and immaturity cell surface molecules and also by the ability to form colonies in vitro. Although increased numbers of CECs correlate with other markers of vascular disease, questions remain regarding the precise definition, cell biology and origin of CECs. For example, they may be damaged, necrotic or apopototic, or alive, and could possess procoagulant and/or proinflammatory properties. However, since these cells seem to be representative of in situ endothelium, their phenotype may provide useful information. Indeed, whatever their phenotype, there is growing evidence that CECs may well be a novel biomarker, the measurement of which will have utility in various clinical settings related to vascular injury. Despite this promise, progress is impeded by the diversity of methodologies used to detect these cells. Accordingly, results are sometimes inconclusive and even conflicting. Nevertheless, increased CECs predict adverse cardiovascular events in acute coronary syndromes, suggesting they may move from being simply a research index to having a role in the clinic. The objective of the present communication is to condense existing data on CECs, briefly compare them with progenitor cells, and summarise possible mechanism(s) by which they may contribute to vascular pathology.